Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant.

About Us

Our News

Keep upto date with our regular news and updated on all our research and product launches

Cell Medica announces the appointment of Luis Borges, PhD, as Chief Scientific Officer

Cell Medica Announces the appointment of Luis Borges, PhD, as Chief Scientific Officer to accelerate R&D for CAR and TCR programmes Luis will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twenty years of experience in the field, including senior positions at Five […]

Read More...

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult Acquisition transfers rights for WT1-TCR cell therapy from CGT Catapult to Cell Medica Collaboration for development, scale-up and manufacturing also established London, 20 June 2017 – Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene […]

Read More...

Investment for Advanced Therapies Summit – Next Generation Cellular Immunotherapy

Investment for Advanced Therapies – Next Generation Cellular Immunotherapy The Summit aims to support investment partnering, clarify market trends, and accelerate the pathway towards a new era of healthcare. Gregg Sando spoke about Cell Medica’s Next Generation Cellular Immunotherapy.

Read More...

Jefferies 2017 Global Healthcare Conference

June 6-9, 2017 – New York, NY Gregg Sando will be presenting at 8:30AM on June 6 at the Jefferies 2017 Global Healthcare Conference The Jefferies 2017 Global Healthcare Conference will be taking place June 6-9 in New York City. http://www.jefferies.com/OurFirm/Conferences/325/318

Read More...

Cell Therapy Manufacturing & Gene Therapy Digital Week – Developing a stringent, commercially viable manufacturing strategy – Anticipating your end point

Cell Therapy Manufacturing & Gene Therapy Digital Week – Developing a stringent, commercially viable manufacturing strategy – Anticipating your end point Alain Pralong, VP Cell Medica, spoke at Cell Gene Digital Week. Watch the on-demand webinar here http://spr.ly/60118gWoH  During this session, Dr. Alain Pralong discusses: • mAbs and Vaccines -what is the current status? • Cell & […]

Read More...

Cell Therapy Manufacturing & Gene Therapy Digital Week – A Closer Look at Orphan ATMP Development, Incentives and Similarity.

Cell Therapy Manufacturing & Gene Therapy Digital Week – A Closer Look  at Orphan ATMP Development, Incentives and Similarity. Clinical Development for Cell, Gene and Immunotherapies A Closer Look  at Orphan ATMP Development, Incentives and Similarity. Alex Bloom of Cell Medica presented at Cell Gene Digital Week. Watch the on-demand webinar here http://spr.ly/60108gWqn  With an […]

Read More...
More News Posts